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Genetic heterogeneity 
and prognostic impact of recurrent 
ANK2 and TP53 mutations 
in mantle cell lymphoma: 
a multi‑centre cohort study
Seri Jeong1,13, Yu Jin park2,13, Woobin Yun2, Seung‑Tae Lee2, Jong Rak choi2, Cheolwon Suh3, 
Jae‑cheol Jo4, Hee Jeong cha5, Jee‑Yeong Jeong6, HeeKyung chang7, Yoon Jin cha8, 
Hyerim Kim9, Min‑Jeong park1, Wonkeun Song1, Eun‑Hae cho10, Eun‑Goo Jeong10, 
Junnam Lee10, Yongmin park11, Yong Seok Lee11, Da Jung Kim12 & Ho Sup Lee12*
The molecular features of mantle cell lymphoma (MCL), including its increased incidence, and complex 
therapies have not been investigated in detail, particularly in East Asian populations. In this study, 
we performed targeted panel sequencing (TPS) and whole‑exome sequencing (WES) to investigate 
the genetic alterations in Korean MCL patients. We obtained a total of 53 samples from MCL patients 
from five Korean university hospitals between 2009 and 2016. We identified the recurrently mutated 
genes such as SYNE1, ATM, KMT2D, CARD11, ANK2, KMT2C, and TP53, which included some known 
drivers of MCL. The mutational profiles of our cohort indicated genetic heterogeneity. The significantly 
enriched pathways were mainly involved in gene expression, cell cycle, and programmed cell death. 
Multivariate analysis revealed that ANK2 mutations impacted the unfavourable overall survival 
(hazard ratio [HR] 3.126; P = 0.032). Furthermore, TP53 mutations were related to worse progression‑
free survival (HR 7.813; P = 0.043). Among the recurrently mutated genes with more than 15.0% 
frequency, discrepancies were found in only 5 genes from 4 patients, suggesting comparability of the 
TPS to WES in practical laboratory settings. We provide the unbiased genetic landscape that might 
contribute to MCL pathogenesis and recurrent genes conferring unfavourable outcomes.
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin’s lymphoma (NHL) accounting for 5–7% of all 
 NHLs1. Although MCL is uncommon (0.64/100,000 person-years), there has been a 130.9% rise in its incidence 
in recent  years2. Higher incidence rates have been seen in Caucasians (153.0%), Asians (96.4%), and the elderly 
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(429.2%). Patients with MCL treated with standard therapies have a limited duration of remission, and also show 
frequent relapses, resulting in a short median overall survival (OS) of 4–5  years3.
Classical MCL expresses the hallmark t(11:14)(q13;q32) chromosomal  translocation4. However, the pathogen-
esis of MCL is complex and the alterations in the genes involved in DNA damage response (ataxia telangiectasia 
mutated [ATM], checkpoint kinase 2 [CHK2], and TP53) and cell survival signalling pathways (Bruton’s tyrosine 
kinase [BTK], mammalian target of rapamycin [mTOR], nuclear factor-κB [NF-κB], tumour necrosis factor 
[TNF], and NOTCH) also play crucial  roles5. Moreover, MCL patients exhibit diverse responses to therapies and 
clinical  courses6,7, which has not been completely incorporated by current risk stratification tools. Therefore, it 
is essential to investigate the genetic landscape of this heterogeneous disease to gain insight into the molecular 
pathogenesis and to predict the prognosis of MCL patients.
Targeted panel sequencing (TPS) and whole-exome sequencing (WES) have been used as influential tools 
for discovering the molecular mechanisms of haematologic  malignancies8-12. Differences in genomic signatures 
according to ethnicity have been found in previous MCL  studies8-16. However, there has been no report of 
the genetic landscape in Korean or East-Asian MCL patients, which are rarely reported as study populations. 
Therefore, we aimed to investigate the genetic alterations in MCL patients in Korea using both TPS and WES. 
Prognostic factors including clinical parameters and gene mutations were also analysed. Furthermore, we con-
ducted a comparative analysis between TPS and WES to determine the ideal prediction tool for MCL patients.
Results
Clinical characteristics. The clinical data of the 50 MCL patients enrolled in this study are summarized in 
Table 1. The median age was 62.5 years. This cohort predominantly consisted of men (70.0%) and patients with 
advanced stages (stage IV, 68.0%). The typical t(11;14)(q13;q32) translocation was found in 6 patients (12.0%). 
One patient had +8,t(8;14)(q24;q32) chromosomal aberration. These chromosomal abnormalities were identi-
fied by classical cytogenetics, and not by fluorescence in  situ hybridization (FISH). Eleven patients (22.0%) 
belonged to the high risk group according to mantle cell lymphoma international prognostic index (MIPI). Most 
patients (82.0%) received rituximab combined chemotherapy such as R-CHOP and R-hyper-CVAD (Supple-
Table 1.  Clinical data and sample information of patients with mantle cell lymphoma. ASCT, autologous stem 
cell transplantation; CR, complete remission; IPI, international prognostic index; LDH, lactate dehydrogenase; 
MG, microglobulin; MIPI, mantle cell lymphoma international prognostic index; OS, overall survival; 
PD, progressive disease; PFS, progression free survival; PR, partial remission; SD, stable disease. *Data are 
expressed as the median (1st and 3rd quartiles) or number (percentage). a Rituximab combined chemotherapy.
Characteristics Value* Missing*
Age (years) 62.5 (56.9–70.0) 0 (0.0)
Sex, male 35 (70.0) 0 (0.0)
β2-MG, elevated (≥ 254.5 nmol/L) 24 (48.0) 0 (0.0)
LDH, elevated (≥ 4.67 ukat/L) 22 (44.0) 0 (0.0)
Ki-67, high (≥ 30%) 21 (42.0) 17 (34.0)
Cytogenetic aberration 6 (12.0) 0 (0.0)










R-Chemotherapya 41 (82.0) 0 (0.0)
ASCT 9 (18.0) 0 (0.0)
Radiotherapy 5 (10.0) 0 (0.0)
Efficacy 10 (20.0)
 Complete remission 22 (44.0)
 Partial remission 11 (22.0)
 Stable disease 2 (4.0)
 Progressive disease 5 (10.0)
Sample status, relapse 19 (38.0) 18 (36.0)
OS (months) 33.0 (12.8–56.0)
PFS (months) 19.5 (9.9–37.7) 32 (64.0)
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mentary Table S1). The complete and partial remission rates were 44.0% and 22.0%, respectively. The estimated 
OS rates were 62.1% for 3-year, and 55.2% for 5-year.
MCL mutational landscape. A lymphoma panel was performed on 53 formalin-fixed paraffin-embed-
ded (FFPE) samples derived from MCL patients. Among them, WES was conducted on 16 FFPE samples (4 
saliva samples for germline control). The mutational profiles of 53 MCL patients are presented in Fig. 1a, show-
ing genetic heterogeneity. SYNE1, ATM, and KMT2D were the most three common genes having mutations 
in our MCL cohort (69.8%). We analysed these genes using cBioPortal software (https ://www.cbiop ortal .org/
index .do)17. The SYNE1 and KMT2D mutations were frequently found in cutaneous squamous cell carcinoma 
(cSCC), and have also been reported in previous studies on  MCL8,18. The frequencies of SYNE1 (37.7%), and 
KMT2D mutations (32.1%) in our cohort were higher than those in other MCL cohort studies (6.9% for SYNE18, 
and 12% to 23% for KMT2D8–10,12,18). ATM mutations showed a frequency of 34.0% in our cohort, and previous 
MCL studies showed that this gene is consistently mutated with a high frequency (15% to 56%8-16). ANK2 muta-
tions, detected in cSCC and NHL, were present at a higher frequency (22.6%) in our study than in previous MCL 
cohort  studies12. ANK2 encodes ankyrin-2, which plays a crucial role in cell  development12. TP53 mutations 
have been detected in most studies on genomic alterations in  MCL11,12, and this mutation was also reported in 
our cohort (17.0%). Samples obtained from patients who relapsed showed a higher frequency of TP53 mutation 
(26.3%) than primary samples (15.4%). However, the difference was not significant (P = 0.463). Among the fre-
Figure 1.  The mutational spectrum of 53 patients with mantle cell lymphoma. (a) Mutational spectrum 
with frequencies and clinical data. (b) Genes identified in the lymphoma panel only (left) or by whole-exome 
sequencing (WES) only (right).
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quently mutated genes associated with MCL, only SYNE1 (P = 0.020 for Chi-square test, and hazard ratio [HR] 
0.167; P = 0.025 for binary logistic regression) was significantly related to primary samples, when compared to 
relapsed samples. Regarding to mean variant allele frequency, the values of relapsed samples were significantly 
higher than those of primary samples for SYNE1 (32.4% vs. 60.2%; P = 0.013), ANK2 (35.0% vs. 55.7%; P = 0.042), 
and TP53 (30.1% vs. 72.4%; P = 0.024) mutations. Ten out of 53 patients harboured KMT2C and MAP1B muta-
tions, which were frequently found in patients with small cell lung  cancer19 and NHL 18,20-23. The frequencies 
of recurrently mutated genes including ATM, BIRC3, CCND1, KMT2D, NOTCH1, TP53, TRAF2, UBR5, and 
WHSC1 in other MCL studies compared to those in our study are presented in Supplementary Table S2.
Genes that were detected only in one of the lymphoma panel or WES are presented in Fig. 1b. Among the 
recurrently mutated genes with more than 15.0% frequency, discrepancies were found in only 5 genes from 4 
patients, which showed the comparability of the two methods.
Prognostic risk factors. Univariate and multivariate analyses were performed to investigate the risk factor 
for the prognosis of MCL patients (Table 2). OS and progression-free survival (PFS) were assigned as independ-
ent factors for prognosis, while clinical and genetic mutations were considered as co-variates. The factor that 
significantly correlated with worse OS was old age (HR 1.086; P = 0.009). High tumour proliferation index (Ki-
67 ≥ 30%) and high risk group of MIPI, known as factors of poor prognosis, showed 5.372 and 2.341 of HR for 
Table 2.  Univariate and multivariate analyses for overall survival and progression-free survival in mantle cell 
lymphoma patients. ASCT, autologous stem cell transplantation; CI, confidence interval; HR, hazard ratio; IPI, 
international prognostic index; LDH, lactate dehydrogenase; MG, macroglobulin; MIPI, mantle cell lymphoma 
international prognostic index; NA, not applicable due to the paucity of positive or negative data. *Genes with 
a frequency of more than 17.0% and P < 0.05 in univariate analyses for overall survival or progression-free 
survival are indicated in bold. a P < 0.05 in multivariate analyses for overall survival or progression-free survival.
Factors
Overall survival Progression-free survival
Univariate Multivariate Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age 1.086 (1.019–1.157) 0.009 1.075 (1.002–1.154) 0.044 1.066 (0.975–1.165) 0.153
Sex, male 0.399 (0.147–1.085) 0.063 0.694 (0.165–2.924) 0.617
β2-MG, elevated (≥ 3.0 µg/mL) 2.411 (0.855–6.801) 0.087 2.367 (0.563–9.956) 0.226
LDH, elevated (≥ 280 U/L) 1.490 (0.546–4.069) 0.434 1.655 (0.348–7.873) 0.523
Ki-67, high (≥ 30%) 5.372 (0.666–43.311) 0.077 NA
Cytogenetic aberration 0.609 (0.077–4.487) 0.605 4.500 (0.466–43.482) 0.154
Stage IV 0.722 (0.273–1.910) 0.510 2.680 (0.532–13.512) 0.217
MIPI, high versus low and intermedi-
ate 2.341 (0.744–7.369) 0.135 3.311 (0.383–28.611) 0.249
IPI, high versus low 1.203 (0.420–3.448) 0.731 0.818 (0.197–3.404) 0.782
Rituximab combined chemotherapy 0.423 (0.154–1.167) 0.088 0.844 (0.215–3.305) 0.807
ASCT 0.219 (0.029–1.673) 0.109 1.006 (0.121–8.385) 0.996
Radiotherapy 0.634 (0.139–2.896) 0.553 0.967 (0.198–4.717) 0.967
Genetic mutations*
SYNE1 0.754 (0.261–2.181) 0.601 0.537 (0.065–4.406) 0.556
ATM 0.905 (0.328–2.497) 0.847 0.733 (0.148–3.626) 0.702
KMT2D 1.255 (0.458–3.434) 0.658 0.602 (0.125–2.910) 0.524
PCLO 2.380 (0.910–6.224) 0.069 1.873 (0.499–7.028) 0.345
ANK2a 3.403 (1.255–9.229) 0.011 3.126 (1.105–8.845) 0.032 1.562 (0.387–6.304) 0.528
CARD11 2.554 (0.952–6.855) 0.054 0.863 (0.177–4.198) 0.855
CDH23 0.779 (0.220–2.765) 0.699 0.240 (0.028–2.053) 0.164
ABCA7 0.520 (0.180–1.504) 0.219 0.800 (0.191–3.349) 0.759
CRYBG3 1.348 (0.468–3.881) 0.579 1.514 (0.370–6.190) 0.561
PKHD1L1 0.323 (0.073–1.431) 0.118 0.643 (0.133–3.113) 0.580
ROBO2 2.135 (0.767–5.945) 0.137 1.898 (0.313–11.504) 0.479
KMT2C 4.305 (1.592–11.639) 0.002 2.751 (0.969–7.813) 0.057 6.116 (1.009–37.064) 0.025 3.482 (0.311–39.008) 0.311
LRP1B 1.317 (0.419–4.145) 0.637 0.614 (0.118–3.196) 0.559
MAP1B 1.727 (0.550–5.418) 0.343 15.392 (1.333–177.654) 0.004 12.403 (0.732–210.025) 0.081
MKI67 1.492 (0.480–4.641) 0.486 0.630 (0.077–5.174) 0.665
TCF3 1.099 (0.352–3.429) 0.871 5.604 (0.682–9.942) 0.147
TP53a 1.121 (0.315–3.989) 0.859 9.300 (1.490–58.049) 0.004 7.813 (1.065–57.293) 0.043
DLC1 2.081 (0.705–6.137) 0.175 2.580 (0.429–15.531) 0.283
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OS, respectively. However, their P-values could not reach the predefined 0.05. The recurrently mutated genes 
with a frequency of > 15.0% were also included in our prognostic analysis. ANK2 (HR 3.403; P = 0.011) and 
KMT2C (HR 4.305; P = 0.002) mutations were related to worse OS based on our univariate analysis. In multivari-
ate analysis, ANK2 was determined as an independent predictor (HR 3.126; P = 0.032). Age, and KMT2C show-
ing P-values less than 0.05 in univariate analysis were co-variates for the multivariate analysis for ANK2 gene. 
The patients with ANK2 mutations showed significantly shorter median survival time (26.3 months) than those 
without (124.9 months) (P = 0.010) according to survival analysis.
Regarding to PFS, TP53 (HR 9.300; P = 0.004), KMT2C (HR 6.116; P = 0.025), and MAP1B (HR 15.392; 
P = 0.004) were associated based on univariate analysis. Among them, TP53 was a significant predictor of PFS 
according to multivariate analysis (HR 7.813; P = 0.043). Patients with TP53 mutations had significantly shorter 
median PFS time (8.0 months) than those without (47.5 months) (P = 0.004). The survival curves calculated based 
on patient age and the presence of mutated genes using the Kaplan–Meier method are illustrated in Fig. 2a-f.
Pathways affected by mutations. We conducted functional enrichment analysis of the mutated genes 
in our MCL cohort (Fig. 3a). The specific names of the 25 most significant pathways, which mainly consisted 
of pathways related to gene expression, cell cycle, and programmed cell death, are presented in Supplementary 
Table  S3. TP53, ATM, and KMT2D are mainly involved in gene expression and cell cycle pathways such as 
regulation of TP53 expression and auto-degradation of the E3 ubiquitin ligase COP1. Meanwhile, ANK2 was 
Figure 2.  Kaplan–Meier curves for overall survival and progression-free survival of patients with mantle cell 
lymphoma. Kaplan–Meier curves of (a) age classes for overall survival, (b) ANK2 mutation for overall survival, 
(c) KMT2C mutation for overall survival, (d) KMT2C mutation for progression-free survival, (e) MAP1B 
mutation for progression-free survival, and (f) TP53 mutation for progression-free survival. The presented 
P-values were calculated using the log-rank test.
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found to be involved in pathways related to developmental biology and vesicle-mediated transport. The focused 
locations of amino acid changes on ANK2 and TP53 mutations in this cohort are illustrated in Fig. 3b and c, 
respectively. The changes of p.D3340G and p.3774 M were presented recurrently in MCL patients with ANK2 
mutations.
Discussion
To the best of our knowledge, this is the first study reporting the TPS and WES for comprehensive genomic 
investigation of MCL patients in Korea. We have shown the heterogeneous spectrum of the genetic mutations of 
this form of lymphoma. We have also discovered several molecular mechanisms contributing to its pathogenesis. 
Furthermore, we analysed the impact of recurrent ANK2 and TP53 mutations for clinical prognosis including 
OS and PFS. We also investigated the comparison between TPS and WES to suggest more appropriate labora-
tory settings.
Among the commonly mutated genes in our study, SYNE1, ATM, KMT2D, CARD11, ANK2, ROBO2, 
CRYBG3, KMT2C, TP53, and DLC1 were previously identified in MCL  studies1,8,11,12,18. The mutational profiles 
shown in our cohort including the detected genes, variations, and frequencies showed substantial genetic het-
erogeneity, consistent with previous studies. Mutations in CDH23, ABCA7, LRP1B, MAP1B, MKI67, TCF3, and 
ABCA13, rarely reported in previous MCL studies, presented more than 15.0% in our study. Ethnic variations, 
specimen status, the applied reagents and equipment, sequence depth, and the coverage of the target genes may 
have influenced these differences.
In this study, we most commonly identified SYNE1 mutations (37.7%), which were detected at a rate of 6.9% in 
a previous MCL cohort  study8. The SYNE1 was listed as one of the recurrently mutated genes in MCL and diffuse 
large B-cell lymphoma  literatures1. Furthermore, a study for frequent mutation of histone modifying genes in 
NHL also reported SYNE1  mutation24. This gene, located on 6q25.1–25.2, encodes nesprin-1, which is involved 
Figure 3.  Pathway analysis and amino acid changes resulting from the determined ANK2 and TP53 mutations. 
(a) Pathway analysis of mutational genes with a frequency of more than 15.0% in mantle cell lymphoma 
samples. (b) The location of amino acid changes resulting from ANK2 and (c) TP53 mutations.
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in communication between the nuclear lamina and the  cytoskeleton25. Nesprin-1 is critical for nuclear position-
ing and anchorage. This protein has been correlated in dilated  cardiomyopathy26. In cancers, SYNE1 showed 
medium and high expression in lymphoma patients and likely drive transformation of  lymphoma27. Regarding 
to the relapsed status, the frequency of SYNE1 mutations was lower than that of primary samples. However, the 
mean allele frequency of SYNE1 mutations was significantly increased in relapsed samples compared to initial 
samples. In a previous study, SYNE1 mutations were reported as relapse-associated mutations in paediatric acute 
lymphoblastic  leukaemia28. A minor clone with a SYNE1 mutation was identified at the first relapse, and it became 
dominant at the second relapse. Moreover, Shah et al.29 suggested a plausible role of CD44v-SYNE1-miRNA34a 
axis as biomarkers to diagnose oral cancer at an early stage and predict the early onset of metastasis. Although the 
underlying mechanism of SYNE1 gene is unraveled and the relation to tumourigenesis is controversial, SYNE1 
mutation might be used at least as a biomarker for relapsed status, considering the mean allele frequencies of 
our cohort. Further investigating these results on a larger sample set is necessary.
The second most frequently detected mutation found in our study was in ATM (34.0%), which has been a 
previously identified MCL driver. ATM mutations have been found in 41.4% of Western patients and 37.5% of 
Chinese  patients8,11. The ATM mutations included nonsense and frameshift mutations, similar to those observed 
in previous MCL studies. We found that various mutated forms of ATM were involved in gene expression and 
cell cycle pathways. In particular, this gene encodes a tumour suppressor involved in DNA damage  response30. 
Additionally, ATM mutations are related to the inactivation of the ARF-TP53 tumour suppressor  pathway31. 
These forms have also been reported in different subtypes of lymphoid  malignancies32,33.
KMT2D showed a mutation rate of 32.1% in this study compared to 12–23% in previously reported MCL 
 studies18. The epigenetic modifier, KMT2D, has been identified as an early MCL  driver34. We also frequently 
detected KMT2D nonsense and frameshift mutations in our cohort, supporting its contribution to lymphom-
agenesis. Somatic mutations leading to inactivation of the KMT2D methyltransferase perturb germinal center B 
cell development and promote lymphomagenesis by remodeling the epigenetic landscape of the cancer precursor 
 cells35.
ANK2 and TP53 were significantly related to OS (HR 3.126) and PFS (HR 7.813), respectively. A higher 
mutation frequency (22.6%) was observed in ANK2 encoding ankyrin-212,36. This protein is crucial for the 
localization and membrane stabilization of ion transporters and ion channels, especially in cardiomyocytes. 
Therefore, ankyrin mutations are generally associated with cardiac arrhythmia and sudden cardiac  death37. 
In terms of malignancies, the silencing of ANK2 expression reduced the growth and invasion of pancreatic 
cancer cells, indicating its potential as a target for  therapy38. Further, ANK2 expression levels had a significant 
correlation with the clinical outcome in gastrointestinal  cancer39. Regarding to MCL, 5.6% (3/56) of ANK2 
mutations were identified from the lymph node samples of Caucasian male patients in a previous  study12. The 
described results analyzed by PolyPhen-2 included damaging (1.0), and possibly damaging (0.7) predictions. 
Similar to this study, our cohort also revealed damaging and possibly damaging predictions based on the scores 
analyzed by SIFT (0.001 to 0.034) and PolyPhen-2 (0.627 to 0.999). ANK2 encodes Ankyrin-2, which belongs 
to a family of cytoskeletal proteins mediating linkage of integral membrane proteins with the spectrin-actin 
based skeleton. Ankyrin-2 is involved in pathways associated with a variety of biological activities such as cell 
motility, activation, proliferation, contact, and the maintenance of specialized membrane  domains36. Ankyrin 
repeat domain, a highly conserved membrane-binding domain shared by ankyrin encoding genes, is seemed 
to be directly associated with the binding of ankyrins to various types of proteins. In particular, binding to 
CD44, which is a transmembrane glycoprotein mediating lots of important activities of tumour cells, has been 
reported. This interaction was responsible for a more severe malignant phenotype in cancer  cells40. Regarding to 
cancers, ankyrins influence on signal transduction, cell adhesion, membrane transport, cell growth, migration 
and metastasis of cancer  cells38,40. In terms of relapse, some breast cancer samples in the poor prognosis group 
revealed significantly higher ANK2 expression, indicating that ANK2 may be related to personalized relapse 
 mechanism41. Cao et al.42 demonstrated that signaling pathways including ANK2 were modulated by miR-647 
and mediated the proliferation and metastasis of gastric cancer cells. In our study, the mean allele frequencies 
of ANK2 mutations were significantly increased in relapsed samples, suggesting its oncogenic function in lym-
phomagenesis. However, further investigations are required with large sample sizes to validate the impact of 
ANK2 mutations in MCL patients.
With respect to PFS, we found that TP53 was found to be an efficient predictor based on our multivariate 
analysis. Several studies into MCL have demonstrated the association of TP53 mutations with poor clinical 
 outcomes11,43. TP53 alterations were previously associated with a poor prognosis in MCL patients treated with 
standard treatment  modalities44,45. A recent study suggested that allogeneic hematopoietic cell transplantation 
may be a beneficial treatment option for patients with TP53  mutations46. For the younger MCL patients receiv-
ing cytarabine-containing chemotherapy and autologous stem cell transplantation, Ferrero et al.9 developed the 
MIPI-genetic index (MIPI-g), which is a prognostic model integrating MIPI-c prognostic index with genetic 
data (TP53, and KMT2D mutations). Despite being a different study population, we applied the MIPI-g to our 
cohort and found that the high risk patients were significantly related to worse PFS (HR 20.601; P = 0.025) (Sup-
plementary Fig. S1). Based on these findings, we propose that TP53 should be routinely assessed as a molecular 
marker to determine the prognosis, as well as to guide treatment decisions. In respect of relapse, a study on 
younger MCL patients showing 11% of mutation frequency and 26.9% of mean allele frequency for TP53 muta-
tions demonstrated the independent prognostic impact of TP53 mutations on time to  relapse47.
To the best of our knowledge, there has been no previous report investigating TPS and WES concurrently 
using the same lymphoma samples. We compared TPS and WES for the first time in this study to improve the 
practical laboratory settings for the MCL patients. Among the recurrently mutated genes with more than 15.0% 
frequency, we found discrepancies in only 5 genes (TP53, CARD11, SYNE1, MKI67, and ANK2) from 4 patients, 
which shows the comparability of these two settings. However, utilized platforms, the read depth and coverage of 
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the target (365.9X for TPS, and 144.0X for WES) may influence on these results. A previous comparison study, 
which applied TPS and WES to patients with inherited retinal dystrophy, demonstrated that TPS including 291 
genes could be used as a first-tier  test48.
This study had several limitations. The study population was relatively small, reflecting the uncommon inci-
dence of MCL in Korea. Moreover, the samples with unknown state for disease course lessened the available 
analysis, and statistical power. Further study with a much larger number of patients might enable subgroup 
analysis and demonstrate stronger statistical relationship between genetic mutations and prognosis. Additional 
confirmation using Sanger sequencing could not be conducted for mutations with low read depth due to lack of 
remaining DNA samples. Performing this analysis would serve to rule out false positives, and should therefore be 
performed in future studies to confirm the current results. In addition, fresh samples rather than FFPE specimens, 
which were available in this multicenter study, might provide better quality of sequencing data.
In conclusion, we performed TPS and WES for the comprehensive genomic investigation of MCL patients 
using samples from five university hospitals in Korea, a racially homogeneous country of East Asia for the 
first time. This study has revealed the heterogeneous spectrum in the genetic alterations of MCL. We not only 
identified several mutated genes such as SYNE1, ATM, and KMT2D, which contribute to pathogenesis, but also 
showed that recurrent ANK2 and TP53 mutations had negative impacts on the OS and PFS, respectively. In 
particular, our study suggests that TPS may be comparable to WES in practical laboratory settings. In the future, 
the sequencing of these identified genes will benefit MCL patients by improving the prognosis and the choice 
of therapeutic interventions.
Methods
Patients and sample preparation. A total of 53 samples were collected from MCL patients from five 
university hospitals in Korea between March 2009 and October 2016. The FFPE specimens that were stored at 
the Kosin University Gospel Hospital (n = 26), Asan Medical center (n = 11), Ulsan University Hospital (n = 8), 
Gangnam Severance Hospital (n = 6), and Pusan National University Hospital (n = 2) were obtained. The MCL 
samples were confirmed after a diagnosis was made based on the criteria established by the World Health Organ-
ization classification with mantle zone B cell  phenotypes49. As the chromosomal aberrations were identified 
by classical cytogenetics, it might have been affected by laboratory settings such as sample state, resolution of 
the image, and interpretation, additional pathological confirmation by pathologists from the Kosin University 
Gospel Hospital was conducted. Further, pathologists also confirmed that all samples were at least positive for 
cyclin D1. The tested samples were lymph nodes containing more than 80% tumour cells, as confirmed by the 
pathologists.
Records of medical visits, demographic information, and clinical data were collected and reviewed for all 
patients diagnosed with MCL. The sample selection procedure used for evaluating the genetic and prognostic 
parameters is shown in Supplementary Fig. S2. This study was approved by the independent Institutional Review 
Board of Kosin University Gospel Hospital (KUGH 2017-02-011) and conducted in accordance with the Dec-
laration of Helsinki. We obtained informed consents from all the MCL patients and personal information was 
protected and kept anonymous.
TPS and WES. A total of 588 genes known to be related to lymphoma were included in our gene panel; the 
genes are listed in Supplementary Table S4. The targeted lymphoma panel consisted of frequently mutated genes 
in the previously reported 26 studies of lymphoma including particularly  MCL1,8,10-12,18,21,50-68. The mutated genes 
in lymphoma samples deposited in databases such as Catalogue of Somatic Mutations in Cancer (COSMIC), 
ClinVar, and Human Gene Mutation Database (HGMD) were also selected for broader range of targets of TPS. 
Briefly, the sequencing data were analysed as follows. Genomic DNA was extracted from 55 FFPE tissue samples 
using a deparaffinization solution and the QIAamp Blood DNA mini kit (Qiagen, Hilden, Germany). We con-
structed genomic DNA libraries and captured the custom lymphoma panel using the Library Preparation Kit 
(Celemics, Seoul, Korea). The pooled libraries were sequenced using a NextSeq sequencer (Illumina, San Diego, 
CA, USA) and the NextSeq Reagent Kit v2 (500 cycles). The average read depth of 53 samples was 365.9X. The 
read depths and coverages per samples are presented in Supplementary Table S5.
The Agilent SureSelect Human All Exon platform (Agilent Technologies Inc., Santa Clara, CA, USA) was used 
for WES to capture the target DNA samples and generate standard exome libraries. The entire exome regions for 
12 FFPE tumour tissues and 4 saliva samples from 12 MCL patients were sequenced using the HiSeq 2500 plat-
form with a paired-end read protocol (Illumina). The saliva samples were prepared using AccuSaliva collection 
kits (AccuGene Inc., Incheon, Korea) for normal control. All tumour and normal samples were sequenced with an 
average read depth of 144.0X. The read depths and coverages per samples are shown in Supplementary Table S6.
The filtered reads were aligned to the reference assembly of hg19 reference sequence using BWA software 
(version 0.7.5). Indel realignment and base quality score recalibration were performed using MuTect2 in GATK 
software (version 3.7) to identify somatic single-nucleotide variants (SNVs) based on the Catalogue of Somatic 
Mutations in Cancer (COSMIC)  database69. Short indels were identified using VarScan (version 2.3). The muta-
tions (SNVs and indels) found in each sample were annotated using ANNOVAR software. The quality of the 
mutations in the sequenced BAM files were manually reviewed using Integrated Genomics Viewer (Broad Insti-
tute., Cambridge, MA, USA) to filter out false positives. The mean numbers of mutations detected by TPS and 
WES were 9184.9, and 1023.5, respectively. Among the mutations identified by TPS and WES, the numbers of 
filtered and reported mutations were 698 for TPS, and 291 for WES. The threshold for total read depth of the 
reported mutations was 10X. All single nucleotide polymorphisms with a frequency of > 1% in the Korean Variant 
Archive, 1000 Genomes Project, esp6500 database, and EXAC database were removed. We found no significant 
differences between the mutations that were adjusted with the variations of normal control and those without. 
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The variants that were determined to be pathogenic or likely pathogenic based on the American College of 
Medical Genetics and Genomics, COSMIC, and the Association for Molecular Pathology  classification70 were 
considered causative mutations for MCL. Subsequently, genotype–phenotype correlations were discussed by 
clinical pathologists and haemato-oncologists. The significant mutational profiles of 53 MCL patients includ-
ing variant allele frequency, read depth, and SIFT and PolyPhen-2 predictions are presented in Supplementary 
Table S7. The presented variant of allele frequency was more than 5%.
Pathway and survival statistical analysis. Functional enrichment analysis of the recurrently mutated 
genes was performed using the Reactome  tool71. Descriptive statistics were used for the characteristics and sam-
ple information of the MCL patients. Multivariate Cox proportional-hazards regression models were used to 
examine the factors correlated with OS or PFS. OS was determined from the date of diagnosis to the date of 
death from any causes (event), or the last follow up (censoring). PFS was calculated from the date of treatment 
to the date of disease progression (event), death from any causes (event), or the last follow up (censoring)72 for 
the MCL patients including primary and relapsed patients in our cohort as post relapse survival might lead to 
biased estimates based on the report of García-Albéniz et al.73. The Kaplan–Meier method with log-rank test was 
used to estimate the survival curves. Statistical analyses were performed using RStudio statistical software (ver-
sion 3.6.0; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 24.0; IBM, Armonk, NY, 
USA). Values of P < 0.05 were considered statistically significant.
Data availability
All data generated or analyzed during this study are included in this published article (Tables, Figures, and Sup-
plementary information) and available from the corresponding author on reasonable request. The data discussed 
in this study have been deposited in NCBI’s Sequence Read Archive and are accessible through accession number 
SRR10572983.
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